You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameValrubicin
Accession NumberDB00385  (APRD00662)
TypeSmall Molecule
GroupsApproved
DescriptionValrubicin (N-trifluoroacetyladriamycin-14-valerate, Valstar®) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder. [Wikipedia]
Structure
Thumb
Synonyms
(8S, 10S)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-α-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione 8²-valerate
2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-({2,3,6-trideoxy-3-[(trifluoroacetyl)amino]hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate
Valrubicin
Valrubicina
Valrubicine
Valrubicinum
Valstar
External Identifiers
  • AD 32
  • NSC 246131
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ValstarSolution, concentrate40 mg/mLIntravesicalEndo Pharmaceuticals Solutions Inc.1998-10-01Not applicableUs
ValtaxinSolution40 mgIntravesicalEndo Pharmaceuticals Solutions Inc2001-04-23Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII2C6NUM6878
CAS number56124-62-0
WeightAverage: 723.651
Monoisotopic: 723.213874712
Chemical FormulaC34H36F3NO13
InChI KeyZOCKGBMQLCSHFP-KQRAQHLDSA-N
InChI
InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1
IUPAC Name
2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-{[(2R,4S,5S,6S)-5-hydroxy-6-methyl-4-(2,2,2-trifluoroacetamido)oxan-2-yl]oxy}-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate
SMILES
[H][C@@]1(C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=C(OC)C=CC=C1C3=O)C(=O)COC(=O)CCCC)O[[email protected]]1C[[email protected]](NC(=O)C(F)(F)F)[[email protected]](O)[[email protected]](C)O1
Pharmacology
IndicationFor the treatment of cancer of the bladder.
Structured Indications
PharmacodynamicsValrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.
Mechanism of actionValrubicin is an anthracycline that affects a variety of inter-related biological functions, most of which involve nucleic acid metabolism. It readily penetrates into cells, where after DNA intercalation, it inhibits the incorporation of nucleosides into nucleic acids, causes extensive chromosomal damage, and arrests cell cycle in G2. Although valrubicin does not bind strongly to DNA, a principal mechanism of its action, mediated by valrubicin metabolites, is interference with the normal DNA breaking-resealing action of DNA topoisomerase II.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNANucleotideyes
intercalation
Humannot applicabledetails
DNA topoisomerase 2-alphaProteinyes
inhibitor
HumanP11388 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding>99%
Metabolism

Valrubicin is metabolized to two primary metabolites: N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol.

SubstrateEnzymesProduct
Valrubicin
Not Available
N-trifluoroacetyladriamycinolDetails
Valrubicin
Not Available
N-trifluoroacetyladriamycinDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityThe primary anticipated complications of overdosage associated with intravesical administration would be consistent with irritable bladder symptoms. Myelosuppression is possible if valrubicin is inadvertently administered systemically or if significant systemic exposure occurs following intravesical administration (e.g., in patients with bladder/rupture perforation). The maximum tolerated dose in humans by either intraperitoneal or intravenous administration is 600 mg/m2.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
AcetovanilloneAcetovanillone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Valrubicin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
Alendronic acidValrubicin may increase the hypocalcemic activities of Alendronic acid.Approved
AmdinocillinThe serum concentration of Valrubicin can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of Valrubicin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Valrubicin.Approved, Investigational
AmpicillinThe serum concentration of Valrubicin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AnisodamineAnisodamine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Valrubicin.Investigational
ApremilastApremilast may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational
Atracurium besylateValrubicin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Valrubicin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Valrubicin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Valrubicin can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational
BenoxaprofenBenoxaprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Valrubicin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Valrubicin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicillin PotassiumThe serum concentration of Valrubicin can be decreased when it is combined with Benzylpenicillin Potassium.Approved
Benzylpenicilloyl PolylysineThe serum concentration of Valrubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
Betulinic AcidBetulinic Acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Valrubicin.Approved, Investigational
Botulinum Toxin Type AValrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BValrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Valrubicin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Valrubicin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Valrubicin.Approved
CarbenicillinThe serum concentration of Valrubicin can be decreased when it is combined with Carbenicillin.Approved
CarboplatinValrubicin may increase the ototoxic activities of Carboplatin.Approved
CarindacillinThe serum concentration of Valrubicin can be decreased when it is combined with Carindacillin.Approved
CarprofenCarprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Vet Approved
Cisatracurium besylateValrubicin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Valrubicin.Approved
ClodronateValrubicin may increase the hypocalcemic activities of Clodronate.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Valrubicin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateValrubicin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Valrubicin can be decreased when it is combined with Cyclacillin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Valrubicin.Approved, Investigational
CyclosporineValrubicin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
DecamethoniumValrubicin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Valrubicin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Valrubicin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DiflunisalDiflunisal may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Valrubicin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Valrubicin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Valrubicin.Approved, Investigational
Domoic AcidValrubicin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideValrubicin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
E6201E6201 may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
EbselenEbselen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
EpirizoleEpirizole may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Valrubicin.Approved
EtanerceptEtanercept may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational
Etidronic acidValrubicin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
exisulindexisulind may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
FenbufenFenbufen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
FloctafenineFloctafenine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Valrubicin can be decreased when it is combined with Flucloxacillin.Approved
FlunixinFlunixin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Vet Approved
FlurbiprofenFlurbiprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Valrubicin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Valrubicin.Approved, Vet Approved
Gallamine TriethiodideValrubicin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
HigenamineHigenamine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
HMPL-004HMPL-004 may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
IbandronateValrubicin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Valrubicin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
IndomethacinIndomethacin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Valrubicin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
LeflunomideLeflunomide may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
LornoxicamLornoxicam may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Valrubicin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
MecamylamineValrubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Valrubicin which could result in a higher serum level.Withdrawn
MeticillinThe serum concentration of Valrubicin can be decreased when it is combined with Meticillin.Approved
MetocurineValrubicin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideValrubicin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Valrubicin can be decreased when it is combined with Mezlocillin.Approved
MivacuriumValrubicin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
NafcillinThe serum concentration of Valrubicin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
NeosaxitoxinValrubicin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
OlopatadineOlopatadine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Valrubicin which could result in a higher serum level.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Valrubicin.Approved
OxacillinThe serum concentration of Valrubicin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Valrubicin.Approved, Vet Approved
PamidronateValrubicin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumValrubicin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
PhenoxymethylpenicillinThe serum concentration of Valrubicin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational
PipecuroniumValrubicin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Valrubicin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Valrubicin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational
PivampicillinThe serum concentration of Valrubicin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Valrubicin can be decreased when it is combined with Pivmecillinam.Approved
Procaine benzylpenicillinThe serum concentration of Valrubicin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
PropacetamolPropacetamol may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
PTC299PTC299 may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
PyrantelValrubicin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumValrubicin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Valrubicin which could result in a higher serum level.Experimental, Investigational
RisedronateValrubicin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumValrubicin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
SeratrodastSeratrodast may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational
SRT501SRT501 may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
SuccinylcholineValrubicin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Valrubicin can be decreased when it is combined with Sulbactam.Approved
SulfasalazineSulfasalazine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Valrubicin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Withdrawn
TazobactamThe serum concentration of Valrubicin can be decreased when it is combined with Tazobactam.Approved
Technetium tc 99m etidronateValrubicin may increase the hypocalcemic activities of Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateValrubicin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.Approved
TenofovirThe serum concentration of Valrubicin can be increased when it is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Valrubicin can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
TiludronateValrubicin may increase the hypocalcemic activities of Tiludronate.Approved, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Valrubicin.Approved
TranilastTranilast may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Valrubicin.Approved, Investigational
Trisalicylate-cholineTrisalicylate-choline may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
TubocurarineValrubicin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Valrubicin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Valrubicin.Approved
VecuroniumValrubicin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidValrubicin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Francesca Scarpitta, Csilla Nemethne Racz, “Crystalline forms of valrubicin and processes for their preparation.” U.S. Patent US20080139490, issued June 12, 2008.

US20080139490
General ReferencesNot Available
External Links
ATC CodesL01DB09
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (80 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8596
Blood Brain Barrier-0.8907
Caco-2 permeable-0.6894
P-glycoprotein substrateSubstrate0.8165
P-glycoprotein inhibitor INon-inhibitor0.5747
P-glycoprotein inhibitor IINon-inhibitor0.5584
Renal organic cation transporterNon-inhibitor0.9348
CYP450 2C9 substrateNon-substrate0.8061
CYP450 2D6 substrateNon-substrate0.7947
CYP450 3A4 substrateSubstrate0.7203
CYP450 1A2 substrateNon-inhibitor0.7239
CYP450 2C9 inhibitorNon-inhibitor0.8228
CYP450 2D6 inhibitorNon-inhibitor0.9016
CYP450 2C19 inhibitorNon-inhibitor0.7565
CYP450 3A4 inhibitorNon-inhibitor0.6895
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7154
Ames testNon AMES toxic0.5421
CarcinogenicityNon-carcinogens0.9272
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.8652 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9846
hERG inhibition (predictor II)Inhibitor0.5129
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Endo pharmaceutical solutions inc
Packagers
Dosage forms
FormRouteStrength
Solution, concentrateIntravesical40 mg/mL
SolutionIntravesical40 mg
Prices
Unit descriptionCostUnit
Valstar 40 mg/ml vial219.96USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point116-117 °CNot Available
water solubilityinsolubleNot Available
logP2.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0325 mg/mLALOGPS
logP2.67ALOGPS
logP4.49ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)8ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area215.22 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity168.03 m3·mol-1ChemAxon
Polarizability69.2 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassAnthracyclines
Sub ClassNot Available
Direct ParentAnthracyclines
Alternative Parents
Substituents
  • Anthracyclinone-skeleton
  • Anthracycline
  • Tetracenequinone
  • 1,4-anthraquinone
  • 9,10-anthraquinone
  • Anthracene
  • Glycosyl compound
  • O-glycosyl compound
  • Tetralin
  • Anisole
  • Phenol ether
  • Aryl ketone
  • Fatty acid ester
  • Alkyl aryl ether
  • Alpha-acyloxy ketone
  • Phenol
  • Benzenoid
  • Oxane
  • Fatty acyl
  • Monosaccharide
  • Tertiary alcohol
  • Vinylogous acid
  • Alpha-hydroxy ketone
  • Carboxylic acid ester
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Carboxamide group
  • Ketone
  • Monocarboxylic acid or derivatives
  • Acetal
  • Ether
  • Oxacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Polyol
  • Organic nitrogen compound
  • Carbonyl group
  • Organohalogen compound
  • Organofluoride
  • Organonitrogen compound
  • Organooxygen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Alkyl halide
  • Alkyl fluoride
  • Organic oxygen compound
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
intercalation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Brox L, Gowans B, Belch A: N-trifluoroacetyladriamycin-14-valerate and adriamycin induced DNA damage in the RPMI-6410 human lymphoblastoid cell line. Can J Biochem. 1980 Sep;58(9):720-5. [PubMed:7006761 ]
  2. Perabo FG, Muller SC: New agents in intravesical chemotherapy of superficial bladder cancer. Scand J Urol Nephrol. 2005;39(2):108-16. [PubMed:16019763 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:
TOP2A
Uniprot ID:
P11388
Molecular Weight:
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Perabo FG, Muller SC: New agents in intravesical chemotherapy of superficial bladder cancer. Scand J Urol Nephrol. 2005;39(2):108-16. [PubMed:16019763 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23